SGO 2023

Presentations

Tucatinib | Uterine and Cervical Cancer | Poster #162

A phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: uterine and cervical cancer cohorts (SGNTUC-019, trial in progress)